Tempus Expands Moderna-Merck Deal to Support Cancer Vaccine Commercialization
TEM sits 72% above its 52-week low of $40.77 on elevated volume (2.5× avg).
Summary
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support potential commercialization of intismeran autogene (V940/mRNA-4157) with KEYTRUDA. The deal includes sample logistics and, subject to approvals, NGS services. Financial terms were not disclosed. This deepens Tempus's role in a high-profile individualized cancer vaccine program, potentially adding recurring revenue if the therapy is approved. The expansion follows Tempus's $1.5B acquisition of Personalis and its Q2 2026 revenue growth of 22% YoY. Regulatory approval and launch of V940, along with disclosed economics, would be the next major milestones.
At the time of this announcement, TEM was trading at $70.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.